14 Jan

Cleansing Notice

ASX ANNNOUNCEMENT 14 January 2022 Cleansing Statement CardieX Limited (ASX: CDX) ( CardieX , the Company ) advises that on 13 January 2022, it issued a total of 510,205 Fully Paid Ordinary Shares (the Securities ) without disclosure to the recipients under Part 6D.2 of the Corporations Act 2001 (Cth) (the Corporations Act ). The Company hereby gives notice under Section 708A(5) of the Corporations Act that: (a) the Company has issued the Securities without disclosure to the recipients under Part 6D.2 of the Corporations Act; (b) as at the date of this notice, the Company has complied with the provisions of: a. Chapter 2M of the Corporations Act as they apply to the Company; and b. Section 674 of the Corporations Act; and (c) As at the date of this notice there is no information a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and b. that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of: i. the assets and liabilities, financial position and performance, profits and losses and prospects of the body; or ii. the rights and liabilities attaching to the relevant securities. to the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document. Authorised for release by the Board of Directors, and released by Jarrod White For more information please contact: Investor Relations Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au Media Relations Melissa Hamilton melissa.hamilton@mcpartners.com About CardieX CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR·X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2022 launch) .

More from CardieX Limited

Join Listcorp to create a personalised news feed, follow your favourite companies, save useful news, and more.

By joining Listcorp you agree to our Terms & Conditions and Privacy Policy

Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2022 Listcorp. ABN 60 166 140 307

Never miss news from CardieX Limited (ASX:CDX) when you join Listcorp.